Abstract
Cancer is a complex genetic, proteomic, and cellular disease caused by multiple factors via genetic mutations (hereditary or somatic) or environmental factors. The emerging omics technologies are being increasingly used for cancer research and personalized drug discovery, including genomics, epigenomics, proteomics, cytomics, metabolomics, interactomics, and bioinformatics. Recent advances in high-throughput omics technologies have provided new opportunity in the molecular analysis of human cancer in an unprecedented speed and details.
The detection and treatment of cancer is greatly facilitated by the omics technologies. For example, genomics analysis provides clue for gene regulation and gene knockdown for cancer management. The approval of Mammaprint and Oncotype DX indicates that multiplex diagnostic marker sets are becoming feasible. Discovery of the involvement of microRNAs in human cancers has opened a new page for cancer researchers. Some therapeutic drugs targeting on DNA methylation and histone deacetylation are currently undergoing keen studies. Proteomics also plays an important role in cancer biomarker discovery and quantitative proteome-disease relationships provide a mean for connectivity analysis. Fluorescent dye enables a more reliable analysis and it facilitates the progress of biochip and cytomics. The huge amount of information collected by multiparameter single cell flow- or slide-based cytometry measurements serves to investigate the molecular behavior of cancer cell populations. Cancer is also an ideal field of application for metabolite profiling owing to its unique biochemical properties.
It is envisioned that omics technologies will enhance our understanding of molecular signatures of cancer on both qualitative and quantitative patterns. The novel omics technologies have brought powerful abilities to screen cancer cells at the gene, transcript, protein, metabolite, and their interaction network level in searching of novel drug targets, expounding the drug mechanism-of-action, identifying adverse effects in unexpected interaction, validating current drug targets, speeding up the discovery of new targets, exploring potential applications for novel drugs, and enabling the translation from bench to bedside. The field is moving fast, specialized techniques are being developed to integrate omics information and to enable new research avenues that can take advantage of and apply this information to new therapies. In this chapter, different omics technologies are briefly introduced.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cesareni G, Ceol A, Gavrila C et al (2005) Comparative interactomics. FEBS Lett 579:1828–1833
Cho WC (2007a) Cancer biomarker discovery: the contribution of “omics”. BIOforum Eur 11:35–37
Cho WC (2007b) OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6:60
Cho WC (2007c) Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 6:25
Cho WC (2007d) Proteomic approaches to cancer target identification. Drug Discov Today Ther Strateg 4:245–250
Cho WC (2009) Role of miRNAs in lung cancer. Expert Rev Mol Diagn 9:773–776
Cho WC (2010a) Cancer biomarkers (an overview). In: Hayat EM (ed) Methods of cancer diagnosis, therapy and prognosis. Springer, Netherlands
Cho WC (2010b) MicroRNAs as potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol in press
Cho WC (2010c) MicroRNAs in cancer - from research to therapy. BBA - Rev Cancer in press
Cho WC, Cheng CH (2007) Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 4:401–410
Cho WC, Chow AS, Au JS (2009) Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 45:2197–2206
Claudino WM, Quattrone A, Biganzoli L et al (2007) Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 25:2840–2846
Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–298
Finn WG (2007) Diagnostic pathology and laboratory medicine in the age of “omics”: a paper from the 2006 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 9:431–436
Furge KA, Tan MH, Dykema K et al (2007) Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene 26:1346–1350
Futschik ME, Chaurasia G, Herzel H (2007) Comparison of human protein–protein interaction maps. Bioinformatics 23:605–611
González-Díaz H, González-Díaz Y, Santana L et al (2008) Proteomics, networks and connectivity indices. Proteomics 8:750–778
Gowda GA, Zhang S, Gu H et al (2008) Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 8:617–633
Hamacher M, Herberg F, Ueffing M et al (2008) Seven successful years of Omics research: the Human Brain Proteome Project within the National German Research Network (NGFN). Proteomics 8:1116–1117
Hatada I (2006) Emerging technologies for genome-wide DNA methylation profiling in cancer. Crit Rev Oncol 12:205–223
He YD (2006) Genomic approach to biomarker identification and its recent applications. Cancer Biomark 2:103–133
Heck AJ (2008) Native mass spectrometry: a bridge between interactomics and structural biology. Nat Methods 5:927–933
Hsu CN, Lai JM, Liu CH et al (2007) Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma Genes Online). BMC Bioinform 8:66
Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:703–707
Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692
Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48:653–683
Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (2007) Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges. Cancer Treat Rev 33:284–288
Keusch GT (2006) What do -omics mean for the science and policy of the nutritional sciences? Am J Clin Nutr 83:S520–522
Lussier YA, Liu Y (2007) Computational approaches to phenotyping: high-throughput phenomics. Proc Am Thorac Soc 4:18–25
Mei H, Cuccaro ML, Martin ER (2007) Multifactor dimensionality reduction-phenomics: a novel method to capture genetic heterogeneity with use of phenotypic variables. Am J Hum Genet 81:1251–1261
Negrini M, Ferracin M, Sabbioni S et al (2007) MicroRNAs in human cancer: from research to therapy. J Cell Sci 120:1833–1840
Nicholson JK (2006) Reviewers peering from under a pile of omics data. Nature 440:992
Reymond MA, Lippert H (2008) Proteomics in lung cancer. In: Daoud SS (ed) Cancer proteomics: from bench to bedside. Human Press, Totowa, NJ, pp 139–159
Rosenblatt KP, Bryant-Greenwood P, Killian JK et al (2004) Serum proteomics in cancer diagnosis and management. Annu Rev Med 55:97–112
Rosenfeld N, Aharonov R, Meiri E et al (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462–469
Sanchez-Carbayo M (2006) Antibody arrays: technical considerations and clinical applications in cancer. Clin Chem 52:1651–1659
Shih IeM, Wang TL (2005) Apply innovative technologies to explore cancer genome. Curr Opin Oncol 17:33–38
Stransky B, Barrera J, Ohno-Machado L et al (2007) Modeling cancer: integration of “omics” information in dynamic systems. J Bioinform Comput Biol 5:977–986
Tárnok A, Bocsi J, Brockhoff G (2006) Cytomics – importance of multimodal analysis of cell function and proliferation in oncology. Cell Prolif 39:495–505
van der Merwe DE, Oikonomopoulou K, Marshall J et al (2007) Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 96:23–50
van Ravenzwaay B, Cunha GC, Leibold E et al (2007) The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 172:21–28
Wishart DS (2007) Proteomics and the human metabolome project. Expert Rev Proteomics 4:333–335
Wishart DS, Knox C, Guo A et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668–672
Zbuk KM, Eng C (2007) Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7:35–45
Zhang X, Li L, Wei D et al (2007) Moving cancer diagnostics from bench to bedside. Trends Biotechnol 25:166–173
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Cho, W.C.S. (2010). Omics Approaches in Cancer Research. In: Cho, W. (eds) An Omics Perspective on Cancer Research. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2675-0_1
Download citation
DOI: https://doi.org/10.1007/978-90-481-2675-0_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2674-3
Online ISBN: 978-90-481-2675-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)